Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study
Por:
Wägner A.M., Sánchez-Quesada J.L., Benítez S., Bancells C., Ordóñez-Llanos J., Pérez A.
Publicada:
1 ene 2011
Resumen:
A randomized, crossover study compared the effects of atorvastatin, gemfibrozil and their combination on inflammatory markers in type 2 diabetes. C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), secretory phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 (MCP1) and tumor necrosis factor a (TNFa) were measured. Both lipid-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status. © 2011 Elsevier Ireland Ltd.
Filiaciones:
Wägner A.M.:
Endocrinology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Endocrinology Department, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
Department of Medical and Surgical Science, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
Sánchez-Quesada J.L.:
Biomedical Research Institute IIB Sant Pau, Barcelona, Spain
Benítez S.:
Biomedical Research Institute IIB Sant Pau, Barcelona, Spain
Bancells C.:
Biomedical Research Institute IIB Sant Pau, Barcelona, Spain
Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona, Barcelona, Spain
Ordóñez-Llanos J.:
Biomedical Research Institute IIB Sant Pau, Barcelona, Spain
Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona, Barcelona, Spain
Pérez A.:
Biomedical Research Institute IIB Sant Pau, Barcelona, Spain
CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Spain
|